Science & Technology

XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

Department of Health and Human Services — National Institutes of Health

Opportunity #: 1R44AI179564-01

Award Ceiling

$3.0M

Award Floor

$3.0M

Close Date

Jul 31, 2026

138 days left

Total Funding

$3.0M

Expected Awards

Posted Date

Aug 17, 2023

Cost Sharing Required

Grants.gov ID

sbir-1R44AI179564-01

Description

SBIR Phase Phase II award: "XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies" awarded to EXAVIR THERAPEUTICS INC. in OMAHA, Nebraska. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $3,049,975. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.